Table 1 Safety of CXL in thin corneas
Author, year | No. of eyes | Surgical procedures | Follow up (months) | VA and topography changes | Endothelial loss | Other complications |
|---|---|---|---|---|---|---|
Kymionis, et al. 2012 [38] | 14 | Conventional | 12 | UDVA and CDVA improved, Kmean reduced | Yes | No |
Hafezi, et al. 2009 [30] | 20 | Hypoosmolar riboflavin solution | 6 | Kmax stable or reduced | – | No |
Raiskup and Spoerl 2011 [42] | 32 | Hypoosmolar riboflavin solution | 12 | CDVA and Kmax stable | – | No |
Wu, et al. 2014 [43] | 15 | Hypoosmolar riboflavin solution | 12 | 1 eye lost 1 line CDVA, the rest remained stable or improved, Kmax and Kmin reduced | No | No |
Soeters and Tahzib 2015 [48] | 13 | Hypoosmolar riboflavin solution | 12 | CDVA improved, Kmax, Kmin and Kmean remain stable | No | No |
Gu, et al. 2015 [45] | 8 | Hypoosmolar riboflavin solution | 3 | CDVA stable, Kmax stable | Yes | No |
Filippello, et al. 2012 [28] | 20 | Transepithelial CXL | 18 | UDVA and CDVA improved, keratometry values decreased | No | No |
Spadea and Mencucci 2012 [31] | 16 | Transepithelial CXL | 6–12 | UDVA and CDVA improved, Kmax reduced | No | No |
Kymionis, et al. 2009 [29] | 2 | Custom epithelial debridement | 9 | Topography stable | No | No |
Kaya, et al. 2011 [69] | 2 | Custom epithelial debridement | 1 | – | – | No |
Mazzotta and Ramovecchi 2014 [70] | 10 | Custom epithelial debridement | 12 | UDVA, CDVA stable, Kmean reduced | No | No |
Jacob, et al. 2014 [73] | 14 | Contact lens-assisted | 6–7 | CDVA stable, Kmax stable | No | No |